Phlegmasia cerulea dolens complicated by methylenetetrahydrofolate reductase genetic mutation

Jason A. Fried, Lauren M. Wright

ABSTRACT

Introduction: Deep venous thrombosis (DVT) is the formation of a blood clot within a deep vein. Phlegmasia cerulea dolens (PCD) represents a critical acute consequence of DVT. The PCD is a condition caused by massive iliofemoral thrombosis that produces severe venous congestion and obstruction of arterial flow; eventually, causing ischemia in the affected extremity. The treatment goals of PCD are to restore venous outflow by removing thrombus burden, prevent additional thrombus formation, and maintain collateral circulation. However, no therapeutic algorithms exist for PCD.

Case Report: We report PCD in a 55-year-old male with a significant past medical history for multiple venous thromboembolisms, requiring placement of an inferior vena cava filter and lifetime anticoagulation. Clinical presentation and accompanying venous duplex results led to the diagnosis of PCD. The 9th American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy created guidelines for treatment of acute DVT in the absence of gangrene. Guidelines advise to withhold thrombolysis and percutaneous or surgical procedure until treatment with therapeutic heparin anticoagulation proves to be inadequate. Conservative treatment with therapeutic anticoagulation was unsuccessful. therefore, catheter directed thrombolytic therapy, venoplasty, and stent placement were implemented.

Conclusion: Due to possible associated morbidity and mortality, it is recommended to implement therapy soon after diagnosis of PCD. It is hoped that this report will provide guidance in management and assist to develop an evidence-based treatment algorithm for PCD.

International Journal of Case Reports and Images (IJCRI)

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.

Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations.

IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor.

Website: www.ijcasereportsandimages.com
Phlegmasia cerulea dolens complicated by methylenetetrahydrofolate reductase genetic mutation

Jason A. Fried, Lauren M. Wright

ABSTRACT

Introduction: Deep venous thrombosis (DVT) is the formation of a blood clot within a deep vein. Phlegmasia cerulea dolens (PCD) represents a critical acute consequence of DVT. The PCD is a condition caused by massive iliofemoral thrombosis that produces severe venous congestion and obstruction of arterial flow; eventually, causing ischemia in the affected extremity. The treatment goals of PCD are to restore venous outflow by removing thrombus burden, prevent additional thrombus formation, and maintain collateral circulation. However, no therapeutic algorithms exist for PCD. Case Report: We report PCD in a 55-year-old male with a significant past medical history for multiple venous thromboembolisms, requiring placement of an inferior vena cava filter and lifetime anticoagulation. Clinical presentation and accompanying venous duplex results led to the diagnosis of PCD. The 9th American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy created guidelines for treatment of acute DVT in the absence of gangrene. Guidelines advise to withhold thrombolysis until treatment with therapeutic heparin anticoagulation proves to be inadequate. Conservative treatment with therapeutic anticoagulation was unsuccessful. Therefore, catheter directed thrombolytic therapy, venoplasty, and stent placement were implemented. Conclusion: Due to possible associated morbidity and mortality, it is recommended to implement therapy soon after diagnosis of PCD. It is hoped that this report will provide guidance in management and assist to develop an evidence-based treatment algorithm for PCD.

Keywords: Deep venous thrombosis, Hypercoagulable, Phlegmasia cerulea dolens, Thrombolysis

How to cite this article

Fried JA, Wright LM. Phlegmasia cerulea dolens complicated by methylenetetrahydrofolate reductase genetic mutation. Int J Case Rep Imag 2016;7(5):314–317.

Article ID: Z01201605CR10643JF

doi:10.5348/ijcri-201655-CR-10643

INTRODUCTION

Deep venous thrombosis (DVT) is the formation of a blood clot within a deep vein [1]. Principles of Virchow’s triad—venous stasis, hypercoagulability, and endothelial injury—are postulated as the cause of venous
thrombosis. Non-specific physical examination findings of the extremity may include pain, swelling, erythema, prominent superficial veins, pain with passive dorsiflexion, and peripheral cyanosis [2]. Phlegmasia cerulea dolens (PCD) represents a critical acute consequence of DVT. PCD—“blue, painful leg” or “blue phlebitis” [3]—is a condition caused by massive iliofemoral thrombosis that produces severe venous congestion and obstruction of arterial flow; eventually, causing ischemia in the affected extremity [2, 3]. The PCD is an uncommon but fulminate manifestation of venous thrombosis, with high morbidity and mortality, and without a developed standard of care [3–5].

CASE REPORT

A 55-year-old male presented to the emergency department complaining of back pain of one day duration. Patient described the pain as severe, dull, with radiation to left buttock. Associated symptoms are paresthesias of bilateral lower extremities, left lower quadrant abdominal pain, and shortness of breath. Patient was a non-smoker with a past medical history significant for coronary artery disease, myocardial infarction status post four vessel coronary artery bypass graft, diabetes mellitus, congestive heart failure, cocaine abuse with cessation six months prior to admission, and multiple venous thromboembolisms requiring placement of an inferior vena cava filter and lifetime anticoagulation—rivaroxaban.

Physical examination revealed tenderness to palpation of left abdomen, bilateral flanks, and lumbar spine. Vascular examination included bilateral warm lower extremities, capillary refill less than two seconds, palpable femoral and posterior tibial (PT) pulses with dorsalis pedis (DP) Doppler signals, and no neurologic deficits. Vital signs and cell counts were within normal limits with a lactate acid of 3.1 mmol/L. Computed tomography (CT) scan of the abdomen and pelvis with intravenous and oral contrast revealed distal para-aortic and left retroperitoneal stranding, interpreted as a probable hematoma.

Patient was admitted to the medicine service with orders to hold anticoagulant therapy. On the second hospital day, patient complained of increasing bilateral leg pain—“tightness”—with subsequent change in vascular examination to bilateral bluish lower extremities which were edematous, tender to palpation, delayed capillary refill, no palpable lower extremity pulses, and bilateral PT Doppler signals. Sensation and motor function remained intact; however, he was unable to bear weight due to extreme pain. Vascular surgery was consulted. Computed tomography angiogram of the aorta with bilateral run-offs revealed diminished blood flow and atherosclerotic changes in the vessels below the knee, more apparent on the left than the right. Lower extremity venous duplex showed DVTs of bilateral lower extremities from the common femoral to distal posterior tibial, peroneal, and gastrocnemius veins.

The patient had not been on anticoagulant therapy due to concerns related to the retroperitoneal hematoma. However, considering the above duplex and clinical findings of PCD, the benefits outweighed the risks and therapeutic heparin [80 units/kg IV bolus, then continuous infusion of 18 units/kg/hr] with leg elevation was initiated. The following day, an interval CT of the abdomen and pelvis with intravenous contrast confirmed stability of the retroperitoneal hematoma. After five days of therapeutic heparin, the patient’s clinical response was inadequate due to progressive pain and discoloration of bilateral lower extremities; therefore, decision was made to provide catheter directed thrombolytic therapy. He was taken to the vascular suite for venogram (Figure 1) and a Cragg–McNamera® (Micro Therapeutics Inc., Irvine, CA) catheter was placed for directed thrombolytic therapy (catheter Alteplase rate of 0.5 mg/hr and sheath heparin rate of 500 U/hr). Serial coagulation profiles were monitored and thrombolytic therapy was adjusted accordingly. Postoperative day-one, the patient returned to the vascular suite for interval venography, which revealed decrease in thrombus burden. Thrombolytic therapy was continued and patient returned to the vascular suite postoperative day-two. Venogram showed a patent right iliac vein and vena cava with IVC filter intact. The left external iliac vein had residual thrombus; therefore, venoplasty with 14/100 LifeStar® stent (Bard Peripheral Vascular, Tempe, Arizona) was deployed with subsequent expansion with a 14/40 Atlas® balloon (Bard Peripheral Vascular, Tempe, Arizona). Completion venography revealed a patent venous system with no extravasation or residual stenosis (Figure 2).

Postoperative course consisted of symptomatic treatment and serial vascular examinations. Etiology of condition remained unclear; therefore, hematology/oncology was consulted to exclude underlying malignancy and hypercoagulable state. Patient was found to be hypercoagulable due to a genetic mutation of methylenetetrahydrofolate reductase. The patient was discharged on postoperative day-six, with resolution of presenting symptoms and instructions for resumption of daily activities without functional limitations and continuation of vitamin-K-antagonist. Follow-up at 2nd month and 20th month revealed no recurrence of clinical symptoms.

DISCUSSION

Pathogenesis

Phlegmasia cerulea dolens (PCD) is a rare syndrome with pathogenesis of massive iliofemoral thrombosis causing total or near total venous occlusion. Subsequently, substantial increase in venous pressure produces parallel increase in tissue pressure with consequential fluid sequestration, edema, compromise of arterial circulation,
and ischemia in the affected extremity [2–4]. Risk factors for development of DVT into PCD include malignancy, hypercoagulable states, previous DVT, trauma, inferior vena cava filter, contraceptive agents, and venous stasis [5]. Of these, malignancy is the most common etiology, with reported rates of 33% [4]. Prompt diagnosis and implementation of treatment is the basis to prevent complications such as gangrene [40–60%], amputation [20–50%], and death [25–40%]—pulmonary embolism being responsible for 30% of deaths [3–6].

Diagnosis

Phlegmasia cerulea dolens (PCD) is classified based on severity—non-complicated, impending venous gangrene, or venous gangrene [4]. Diagnosis is established by physical examination and duplex ultrasonography (US) [3]. The PCD is clinically defined as a triad of acute extremity edema, cyanosis, and ischemic pain [5]. Ultrasonography is considered first-line imaging due to sensitivity and specificity in diagnosis of symptomatic proximal DVTs, 97% and 94% respectively; detection of occlusion in arteries and veins; and ability to characterize flow [7, 8]. Alternative diagnostic imaging being CT scan and magnetic resonance imaging scan, with catheter venography and arteriography being the gold standard due to ability to confirm diagnosis, help direct treatment from mapping of circulation, and be therapeutic [8].

Surgical strategy

The treatment goals of PCD are to restore venous outflow by removing thrombus burden, prevent additional thrombus formation, and maintain collateral circulation [4, 5]. No therapeutic algorithms exist for PCD. However, the 9th American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy created guidelines for the treatment of acute DVT in the absence of gangrene. Guidelines advise to withhold thrombolysis and percutaneous or surgical procedure until treatment with therapeutic heparin anticoagulation proves to be inadequate [9]. Conservative therapies for PCD involve elevation of the affected extremity, therapeutic heparin anticoagulation, and fluid resuscitation [3]. If clinical improvement inadequate or massive thrombosis with impending gangrene at presentation, thrombolysis is indicated. Thrombectomy—percutaneous or surgical—is implemented when there is contraindication to thrombolysis or in conjunction with thrombolysis; furthermore, percutaneous transluminal angioplasty with or without stenting and/or fasciotomy are supplementary treatment options depending resolution of thrombus burden and symptoms [3–6].

Defining optimal treatment with current knowledge is impracticable due to the paucity of data and quality studies [3, 10]. An international registry has been suggested to record all cases of PCD, which would assist with creation of an evidence-based approach to treatment [3]. Overall, further structured reporting of PCD is needed in order to augment understanding and education of the efficacy and safety of treatment strategies.

CONCLUSION

Phlegmasia cerulea dolens (PCD) is an uncommon but critical acute consequence of deep venous thrombosis (DVT). Due to the possible associated morbidity and mortality, prompt diagnosis and implementation of therapy are recommended. It is hoped that this report will provide guidance in management and assist to develop an evidence-based treatment algorithm for PCD.
Author Contributions
Jason Fried – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Revising report critically for important intellectual content, Final approval of the version to be published
Lauren Wright – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2016 Jason Fried et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES
1. Deep vein thrombosis. 2015. [Available at: http://www.merriam-webster.com]
2. Crnenwett JL, Johnston KW. Acute Deep Venous Thrombosis: Pathophysiology and Natural History.

In: Vandy FC, Wakefield TW eds. Rutherford's Vascular Surgery. 7ed. Philadelphia: Saunders/Elsevier; 2010. P. 736–52.
3. Klok FA, Huisman MV. Seeking optimal treatment for phlegmasia cerulea dolens. Thromb Res 2013 Apr;131(4):372–3.
4. Chinsakchai K, Ten Duis K, Moll FL, de Borst GJ. Trends in management of phlegmasia cerulea dolens. Vasc Endovascular Surg 2011 Jan;45(1):5–14.
5. Onuoha CU. Phlegmasia Cerulea Dolens: A Rare Clinical Presentation. Am J Med 2015 Sep;128(9):e27–8.
6. Lorimer JW, Semelhago LC, Barber GG. Venous gangrene of the extremities. Can J Surg 1994 Oct;37(5):379–84.
7. Greenfield LJ, Mulholand MW. Vascular diagnostics. In: Moneta GL ed. Greenfield’s Surgery: Scientific Principles and Practice. 5ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. P. 1514–36.
8. Kalagher SD, Kane DD. Phlegmasia cerulea dolens: before and after lysis. Intern Emerg Med 2015 Feb;10(1):103–4.
9. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 Feb;141(2 Suppl):e419S–94S.
10. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012 Jan;7;379(9810):31–8.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.